



society of hematologic oncology

# **PROGRAMME**

## **5ÈME ÉDITION 2026**

**CONGRÈS EN HÉMATOLOGIE**  
**du 14 au 16 octobre 2026**

**SORBONNE UNIVERSITÉ**  
**AUDITORIUM DU CICSU, 75005 PARIS**



**Mandatée par**  
**l'association ARCADE**

# LE COMITÉ SCIENTIFIQUE



**Présidente** : **Mauricette MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)

- **Amine BELHABRI** (Hématologue, Centre Léon Bérard, Lyon)
- **Sylvain CHOQUET** (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- **Jean-Jacques KILADJIAN** (Hématologue, Hôpital Saint-Louis, Paris)
- **Xavier LELEU** (Hématologue, Centre Hospitalier Universitaire de Poitiers, Poitiers)
- **François-Xavier MAHON** (Hématologue, Institut Bergonié, Bordeaux)
- **Anne-Sophie MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)
- **Sophie PARK** (Hématologue, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble)
- **Christian RECHER** (Hématologue, Institut Universitaire du Cancer de Toulouse, Toulouse)
- **Philippe ROUSSELOT** (Hématologue, Centre Hospitalier de Versailles, Versailles)
- **Pierre SESQUES** (Hématologue, Centre Hospitalier Lyon Sud, Lyon)

## Wednesday 14th october 2026

**09h30 - 10h00** **OPENING**

**10h00 - 10h30** **INTRODUCTION**

**Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)**

- What are the innovations in myeloid diseases since the last SOHO France 2025 conference?

Hagop Kantarjian (Oncology Hematology, Houston - USA)

- The latest news from SOHO

Janet CESAК (Executive director SOHO - USA)

**10h30 - 11h45** **SESSION 1: MYELOPROLIFERATIVE NEOPLASMS**

**Chair: Jean-Jacques KILADJIAN (Hematology, Paris)**

- Essential thrombocythemia: from therapeutic frugality to new horizons

Jean-Jacques Kiladjian (Hematology, Paris) – 20min

- Skin carcinomas complicating treatments for NMPs

Hélène Pasquer (Hematology, Paris) – 20min

- Contribution of AI in the NMP

Vincent Alcazer (Hematology, Pierre-Bénite) – 20 min

- Discussion – 15 min

**11h45 - 12h45** **SYMPOSIUM: TAILORED THERAPEUTIC STRATEGIES FOR MYELOFIBROSIS PATIENTS WITH CYTOPENIA, WHERE WE STAND IN 2026?**

**Chair: Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)**

- Introduction

Mauricette MICHALLET (Hematology, Lyon) – 05 min

- Addressing Cytopenias in Myelofibrosis: From Assessment to Treatment

Laurence LEGROS (Hematology, Kremlin-Bicêtre) – 20 min

- Optimizing Therapeutic Strategies for Clinical Practice

Eolia BRISSOT (Hematology, Paris) – 20 min

- Table ronde - 15 min

**GSK**

**12h45 - 13h45** **LUNCH BREAK & MEET OUR PARTNERS**



**13h45 - 15h00** **SESSION 2 : MYELOYDYSPLASTIC SYNDROMES**

**Chair: Sophie PARK (Hematology, Grenoble)**

- Management of clonal hematopoiesis in clinical practice: GFM recommendations

Aline Renneville (Medical Biology Department and INSERM U1287, Gustave Roussy, Villejuif) – 20 min

- Optimization of pre and post transplantation therapies in mds

Marie Robin (Hematology, Paris) – 20 min

- How to treat CMML: should we target stem or differentiated cells?

Christophe WILLEKENS (Hematology, Villejuif) – 20 min

- Discussion – 15 min

**15h00 - 15h30** **CALL FOR ABSTRACT**

**15h30 - 16h30** **2nd SYMPOSIUM**

**16h30 - 16h50** **COFFEE BREAK & MEET OUR PARTNERS**



**16h50 - 17h20** **THE TREATMENT PROTOCOL FOR AML AT MASSACHUSETTS GENERAL HOSPITAL**

Amir Fathi (Hematology, Boston - USA)

**17h20 - 18h30** **SESSION 3: ACUTE MYELOID LEUKEMIA**

**Chair: Amine BELHABRI (Hematology, Lyon)**

- Functional precision medicine for acute myeloid leukemia

Kevin BOUMEGHAR (Hematology, Paris) – 20 min

- BIG Experience in France: results of BIG-1 and future BIG-2 program

Sarah Bertoli (Hematology, Toulouse) – 20 min

- Results from PARADIGM study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Amir Fathi (Hematology, Boston - USA) – 20 min

- Discussion – 15 min

Thursday 15th october 2026

09h00 - 09h30 **OPENING**

09h30 - 10h25 **SESSION 4: ACUTE LYMPHOBLASTIC LEUKEMIA**

**Chair: Aurélie CABANNES (Hematology, Versailles)**

- First results of the ALL TARGET observatory  
Aurélie Cabannes (Hematology, Versailles) – 15 min
- GRAALL recommendations for relapsed ALL  
Marie Balsat (Hematology, Lyon) – 15 min
- New development of immunotherapies in B-ALL  
Nicolas Boissel (Hematology, Paris) – 15 min
- Discussion – 15 min

10h25 - 10h45 **COFFEE BREAK & MEET OUR PARTNERS**



10h45 - 11h15 **CALL FOR ABSTRACT**

11h15 - 12h30 **SESSION 5: CAR-T CELLS**

**Chair: Pierre SESQUES (Hematology, Lyon)**

- Estimating the real price of CAR-T cells in France: from list price to net price  
Carole-Anne Brugère (Calym/Hematology, Lyon) – 15 min
- Recommendations from the LYSA centered on the place of the CAR-T cells and data on the L2: comparison vs SOC & Axi-liso: sequence?  
Benoît Tessoulin (Hematology, Nantes) – 15 min
- Impact of T cell characteristics on CAR-T cell therapy / Fitness of T in the CAR-T cells?  
Present and future  
Estelle Bourbon (Hematology, Lyon) – 15 min
- MM: CAR-T cells then bispecific? bispecific then CAR-T cells? Upcoming sequence?  
Alexis Talbot (Immuno-hematology, Paris) – 15 min
- Discussion – 15 min

12h30 - 13h45 **LUNCH BREAK & MEET OUR PARTNERS**



13h45 - 14h45 **LET'S TALK : QUESTIONS FROM INTERNS TO THE EXPERTS**

14h45 - 16h10 **SESSION 6: MULTIPLE MYELOMA**

**Chair: Xavier LELEU (Hematology, Poitiers)**

- Towards personalized medicine and cure in multiple myeloma: precision biomarkers and beyond  
Anaïs Schavgoulidze (Medical biology, Toulouse) – 15 min
- Response or resistance! Based on interesting data from RESISTEC. Do we have a predictive response marker, is it useful for real life?  
Ludovic Martinet (Research, Toulouse) – 15 min
- NDMM TE and TI. The IT will replace the autograft, can you convince us?  
Cyrille Touzeau (Hematology, Nantes) – 15 min
- Tomorrow's IT, new ADCs, new CAR-T, Trispe. With the MAJESTEC 3 and TEC LILLE data, do we still need to develop always more, for what? what are the limits of current TTTs that justify developing more, whether it is safety, efficacy, or cost  
Alexis Talbot (Immuno-hematology, Paris) – 15 min
- Discussion – 15 min

16h10 - 16h30 **COFFEE BREAK & MEET OUR PARTNERS**



**16h30 - 17h00** **LAST CALL FOR ABSTRACT**

**17h00 - 18h00** **SESSION 7: LYMPHOMAS**

**Chair: Sylvain CHOQUET (Hematology, Paris)**

- Primary mediastinal NHL

Vincent Camus (Hematology, Rouen) – 15 min

- Relapse/refractory Hodgkin lymphoma

Cédric Rossi (Hematology, Dijon) – 15 min

- Intravascular NHL

Antoine Bonnet (Hematology, Vannes) – 15 min

- Discussion – 15 min

**18h00 - 19h00** **SOCIAL GATHERING**



## Friday 16th october 2026

**09h00 - 09h30** **OPENING**

**09h30 - 10h45** **SESSION 8: CHRONIC MYELOID LEUKEMIA**

**Chair: François-Xavier MAHON (Hematology, Bordeaux)**

- Development of machine learning applied to CML: prognostic and predictive factors

Vincent Alcazer (Hematology, Pierre-Bénite) – 20 min

- New molecules in CML

François-Xavier Mahon (Hematology, Bordeaux) – 20 min

- Individualizing front line therapy of chronic phase CML

Delphine Réa (Hematology, Paris) – 20 min

- Discussion – 15 min

**10h45 - 11h00** **COFFEE BREAK & MEET OUR PARTNERS**



**11h00 - 12h15** **SESSION 09: CHRONIC LYMPHOCYTIC LEUKEMIA**

**Chair: Anne-Sophie MICHALLET (Hematology, Lyon)**

- Should all patients be treated with a fixed duration of CLL as a first-line treatment?

Emmanuelle FERRANT (Hematology, Lyon) – 20 min

- Is there hope for treating Richter syndrome with new innovative therapies?

Pierre FEUGIER (Hematology, Nancy) – 20 min

- Is immunochemotherapy still the gold standard for first-line treatment in MW?

Cécile TOMOWIAK (Hematology, Poitiers) – 20 min

- Discussion – 15 min

**12h15 - 12h25** **AWARD CEREMONY - CALL FOR ABSTRACT**

**12h25 - 13h35** **SESSION 10: CELL THERAPY AND TRANSPLANTATION**

**Follow up and treatments after allo-HSCT for hematological malignancies**

**Chair: Anne HUYNH (SFGM-TC president), (Hematology and Transplantation, Toulouse)**

- Post allo-HSCT monitoring?

Léonardo MAGRO (Hematology and Transplantation, Lille) – 20 min

- Prophylactic treatments after allo-HSCT

Raynier DEVILLIER (Hematology and Transplantation, Marseille) – 20 min

- Treatments of relapse after allo-HSCT

Michael LOSCHI (Hematology and Transplantation, Nice) – 20 min

- Discussion – 15 min

**13h35 - 13h45** **TAKE HOME MESSAGE**